Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including the biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for a total consideration of US $122.5 million. The transaction was executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO service agreement with MacroGenics.
With this acquisition, Bora Biologics, the biologics CDMO franchise of Bora Group, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, along with a development facility in Zhubei, Taiwan. The expanded platform positions Bora Biologics as a fully integrated, end-to-end biologics CDMO offering drug substance and drug product capabilities from development through commercial supply.
"This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
With the addition of the Rockville facility, Bora Biologics supports more than four active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada and the UK, backed by fully integrated QC and analytical capabilities. Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure.
Bora Group intends to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. This strategic move aligns with the company's vision of "Contributing to Better Health All Over the World" and its commitment to sustainable growth through investment in talent, infrastructure, and biologics expansion. For more information about Bora Pharmaceuticals and its CDMO services, visit https://www.bora-corp.com or https://www.boracdmo.com.
